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Abstract  
Objective: Measures of the impact of vasomotor symptoms (VMS) have been used as 
outcomes in clinical trials but have not been compared. This study compares the Hot Flush 
Rating Scale (HFRS), the Hot Flash Related Daily Interference Scale (HFRDIS) and the 
shorter Hot Flash Interference (HFI) scale.  
Methods: Baseline data from two studies included healthy women (menopause transition or 
postmenopause) and breast cancer patients, experiencing VMS. Participants completed 
questionnaires (sociodemographics, HFRS, HFRDIS, HFI, Work and Social Adjustment 
Scale (WSAS), depression (GAD7), anxiety (PHQ9) and use of medical services. 
Results: 169 women (129 with history of breast cancer and 40 without), aged 54.47 
(SD=9.11) took part. They had an average of 66 (SD=40.94) VMS per week, with mean 
HFRS problem rating of 6.53 (SD=1.99), HFRDIS score of 5.36 (SD=2.22) and HFI score of 
6.13 (SD=2.30). HFRS problem-rating, HFRDIS and HFI were significantly associated 
(r=0.61-0.85), had good internal reliability (alpha=0.76-0.91) and significant concurrent 
validity with mood, WSAS and use of medical services. VMS frequency was not associated 
with mood, WSAS nor use of medical services.  
Conclusion: The HFRS Problem-rating scale and the HFI are two brief, three-item measures 
that measure a similar concept of VMS interference/impact, with evidence of reliability and 
validity. 
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Health-related quality of life of women going through the menopause transition and post 
menopause, appears to be influenced by vasomotor symptoms (VMS), to a greater extent than 
stage of menopause per se.1-4 Moreover, it tends to be the impact of VMS, i.e. how much 
they interfere with life or how problematic they are perceived to be, rather than their 
frequency, that is associated with aspects of quality of life 3,5-7. Consequently, these variables 
have been considered as appropriate outcomes in clinical trials of treatments of VMS.8-18 
These patient reported outcomes are particularly relevant to evaluation of behavioural 
treatments which tend to target coping strategies, cognitive appraisal and functioning9,12-18 
For example, following a cognitive behaviour therapy (CBT) intervention for VMS, some 
participants reported that they still had VMS but they hardly noticed them.19  
Measures of impact include: the Hot Flush Rating Scale (HFRS)20, the Hot Flash 
Related Daily Interference Scale (HFRDIS)21 and the Hot Flash Interference (HFI).22  HFRS 
is a self-report measure of VMS frequency and problem-rating over the past week. The Hot 
Flush Rating Scale (HFRS) problem-rating is calculated as the mean of the scores on three 
Likert scales (scores range from 1–10) assessing the extent to which HFNS are problematic, 
distressing and causing interference in daily life. The Hot Flash Related Daily Interference 
Scale (HFRDIS)21, a 10-item questionnaire, assesses the impact of hot flushes on daily 
activities and quality of life in the past week, and the Hot Flash Interference (HFI)22 measure 
is a 3 item shortened version of the HFRDIS. The HFRS problem-rating scale tends to be 
used in UK and European trials, while the HFRDIS tends to be used in the USA, but they 
have been not been directly compared.  
 The current study aims to compare these three measures and to examine their 
interrelationships and concurrent validity in relation to work and social adjustment, anxiety, 
depressed mood and use of medical services (doctor visits).  
 
 3 
     METHODS 
Participants  
 Women with variable menstrual cycles (menopause transition) or who were more than 
one year from their last menstrual period (post-menopause) who were having VMS were 
recruited from two sources: (i) baseline data from women who took part in an unpublished 
student project investigating attentional bias amongst women with VMS recruited via on line 
advertisement (referred to as ‘healthy women’ to distinguish from the breast cancer sample), 
and (ii) baseline data from a multicentre trial of Group CBT for women who had VMS 
following breast cancer treatment (MENOS4), recruited from breast cancer clinics.18 
Inclusion criteria: For both samples, English speaking women, 16 years old or older, having 
problematic VMS for at least 1 month and minimum frequency of 7 flushes per week were 
included. For the breast cancer sample, women with primary breast cancer or ductal 
carcinoma in situ (DCIS) who had completed all primary treatment (surgery and/or 
radiotherapy and/or chemotherapy but may still be receiving adjuvant endocrine therapy or 
Herceptin) were included. Exclusion criteria: non-English speaking women and/or with 
history of medical or psychiatric conditions that would affect their ability to participate. 
 All women were offered a screening assessment and if eligible and interested, were 
sent information, a consent form and a baseline questionnaire, which they completed and 
returned to the research team.  
 Ethical approval for the student project was obtained from Kings College London 
Research Ethics Committee (Research Ethics Committee Reference Number: PNM/11/12-
122) and for MENOS4 from National Research Ethics Service South Central - Hampshire A 
Research Ethics Committee and HRA (ref. [16]/SC/0364), University of Southampton 
Sponsored the study (sponsorship number: 19245). All participants provided written 
informed consent to participate and were free to withdraw at any time. 
 4 
Measures 
 Sociodemographic information included age, ethnicity, relationship status (single, 
partner, married/cohabiting, divorced/widowed/separated), educational level (left school at 
16, or 18 or degree/professional qualifications), employment (working fulltime/part-time or 
not working). Healthy women (n=40) were also asked: How many times in the last 6 months 
have you visited your General Practitioner (GP)? How many times in the last 6 months have 
you visited a hospital doctor?  Have you ever sought help for menopause related problems 
(yes/no)? 
 The Hot Flush Rating Scale (HFRS)20 is a self-report measure of VMS frequency and 
problem-rating over the past week. VMS Frequency has significant correlations with diary 
recordings for hot flushes (r=0.97, p<0.001) and night sweats (r=0.94, p<0.001). 
HFRS Problem-rating is calculated as the mean of the scores on three Likert scales (scores 
range from 1–10) assessing the extent to which HFNS are problematic, distressing and 
causing interference in daily life. Higher scores indicate more problematic VMS. HFRS 
Problem-rating has good test–retest reliability (r=0.8) and internal consistency (alpha=0.87).  
 The Hot Flash Related Daily Interference Scale (HFRDIS), 21 a 10-item 
questionnaire, measures the impact of VMS on daily activities and quality of life in the past 
week. Items include: 1 Work (outside the home and housework), 2 Social activities (time 
with family/friends), 3 Leisure activities (time spent relaxing/doing hobbies), 4 Sleep, 5 
Mood, 6 Concentration, 7 Relations with others, 8 Sexuality, 9 Enjoyment of life, 10 Overall 
quality of life, rated on scales from 0 (do not interfere) to 10 (completely interfere); responses 
are averaged to range from 0 to 10 with higher scores indicating greater interference (score 
range 0–10). Internal consistency has been reported as high, Cronbach alpha= 0.92.21 
 The Hot Flash Interference (HFI) 22 is a 3-item scale (including items 4,5, and 6 from 
the HFRDIS assessing interference with sleep, mood and concentration) which is a shortened 
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validated version of the HFRDIS. Internal consistency alpha=0.82. 
 The Work and Social Adjustment Scale (WSAS)23 is a five-item scale that assesses 
functional impairment, i.e. an individual's ability to perform day-to-day activities including 
(1) work, (2) home management, (3) family and relationship interaction and (4) social and (5) 
private leisure activities, rated on an 8-point Likert scale (0=Not at all, 8=Very Severely). It 
provides the degree of impact of symptoms (VMS in this case) on a given activity.  Score 
range between 0 (no impairment) to 40 (very severe impairment). The WSAS had good 
internal consistency (Cronbach alpha ranging between .70 and .90).  
The Generalized Anxiety Disorder 7 (GAD7) Spitzer et al, 2006) is a seven-item 
screening and severity measure validated for anxiety disorders. Responses were on a 4 point 
Likert scale from 0 ‘not at all’ to 3 ‘nearly every day’. A total score was calculated for each 
participant with scores ranging from 0-4 indicating no anxiety, 5-9 mild anxiety, 10-14 
moderate anxiety and 15-21 as severe anxiety.  
The Patient Health Questionnaire 9 (PHQ9) (Kroenke et al, 2001) is a nine-item 
measure of depression with scores range from 0 to 27. Responses are on a 4 point Likert 
scales from 1 ‘not at all’ to 4 ‘nearly every day’. Depression severity is categorized as: 0-4 no 
depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe and 
20-27 severe (Kroenke et al, 2001).  
The WSAS and help-seeking data were available from the healthy sub-sample only. 
Sociodemographic and questionnaire data were analyzed (descriptive statistics, independent 
sample t-tests and Pearson correlations) using the SPSS statistical software package (version 
18.0). 
 
     RESULTS 
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One hundred and sixty-nine women took part; 40 from the healthy women sample and 129 
from the MENOS4 breast cancer study. The total sample average age was 54.47 (SD=9.11) 
years; the majority (89.3%) identified as white ethnicity, 75.2% were married or cohabiting, 
43% left school at 16 years, 43.6% at 18 years, while 13.3% had degree/professional 
qualifications; 62% were employed (38.6% fulltime and 23.5% part-time). The two samples 
did not differ in age or level of education (above or below age 16 years), depressed mood 
(PHQ9) nor anxiety (GAD7), but more of the breast cancer sample than the healthy sample 
were married (80% vs. 60%; Chi-squ=6.49, p<0.01) and of white ethnicity (96% vs. 72%; 
Chi-squ=19.49, p<0.000).  
 The total sample had mean VMS weekly frequency of 61.33 (SD=40.94), with HFRS 
problem rating of 6.53 (SD=1.99), HFRDIS total score of 5.36 (SD=2.22) and HFI mean 
score of 6.13 (SD=2.30). There were no significant differences (HFRS Problem rating 
p<0.10, HFRDIS p<0.67, HFI p<0.39) between healthy menopausal and breast cancer 
samples on interference measures; the breast cancer sample reported more frequent VMS (64 
vs. 50) but the difference was of marginal significance t=-2.33, p<0.02, 95% CI = -29.95 to -
2.14) 
 The internal reliability alpha coefficients were as follows: HFNS Problem Rating 
0.84, HFRDIS 0.91 and HFI 0.76. Correlations between HFNS frequency, the three 
interference measures and the associations between HFNS measures and measures of 
functioning (WSAS scale, medical help seeking, PHQ9 and GAD7) are shown in Table 1. 
Table 1 about here 
HFRS Problem-rating, HFRDIS and HFI were all significantly associated (r=0.61-0.85 
p<0.001). HFRS Problem-rating was more strongly associated with the HFRDIS (r=0.74 
p<0.001) than the shorter HFI (r=0.61, p<0.001). Interference measures were all significantly 
associated with VMS Frequency but to a lesser degree (r=0.22-0.39).  
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For concurrent validity, VMS Frequency was not significantly associated with any of 
the measures of functioning or medical help-seeking, whereas the HFRS Problem-rating 
Scale, HFRDIS and HFI all had significant associations with WSAS, depression (GAD7) and 
anxiety (PHQ9) and number of doctor visits (GP and hospital combined) in the past 6 
months. The total number of visits to general practitioners and hospital doctors during the 
past 6 months was on average 3.65 (SD=3.40) with a range of 0 to 13.  42% (n=17) of 
women had sought medical help specifically for menopause related problems. Medical help-
seeking for menopause related problems had non-significant associations with HFRS 
Problem-rating (Odds Ratio=1.42 CI 0.99-2.03), and to a lesser extent with HFRDIS 
(OR=1.16 CI 0.87-1.57) and HFI (OR=1.07 CI 0.79-1.45).  
 
     DISCUSSION 
 This study provides evidence to support the use of all three measures of the impact of 
VMS – a concept which includes impact and interference with daily living, and an appraisal 
of how distressing and problematic they are perceived to be. The HFRDIS includes a range of 
situations and contexts that VMS might impact, whereas the HFI focuses on three specific 
items: VMS impact upon sleep, mood and concentration. The HFRS problem-rating assesses 
women’s appraisal of symptoms as problematic, distressing and interfering with daily life. 
The internal reliability and concurrent validity and the correlations between measures suggest 
that, overall, they are reliable and are measuring similar concepts. The term ‘impact of VMS’ 
might capture the concept assessed by these measures. While the HFRS problem-rating is 
more strongly associated with the longer HFRDIS than the shorter HFI, in other respects the 
shorter HFI performs generally as well as the HRDIS, which supports findings of Carpenter 
et al.22  
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 Interestingly HFRS Frequency was associated with measures of VMS impact (r=0.22-
0.39), but not with work and social adjustment, mood nor medical help-seeking. These 
findings provide further evidence that considering frequency of VMS as the only outcome 
measure in clinical trials may fail to capture the important clinically relevant concept of 
impact of the symptoms on women’s lives.26 Some treatments, such as CBT, specifically 
target symptom appraisal and management. Mediation analyses of two trials suggests that 
CBT works mainly by changing symptom perceptions and cognitive appraisals as well as 
using helpful behavioural strategies,27-28 i.e. changes in these variables mediated the 
improvement in VMS problem-rating.  
Limitations include the small sample size particularly for the WSAS and use of 
medical services. It would have been difficult to obtain a general estimate of medical help 
seeking from the breast cancer sample, as this would have been strongly influenced by breast 
cancer appointments. Future research could assess the relative sensitivity to change of the 
three measures in response to treatments and their associations with the single item of 
‘bother’ which has also been found to be highly correlated with the HFRDIS.21 
In conclusion, the results suggest that the three measures appear to measure a similar 
concept of impact of VMS. Short measures tend to be preferred in clinical trials; HFRS 
problem-rating and the HFI are both short reliable measures of the impact of vasomotor 
symptoms, with evidence of concurrent validity.  
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Table 1 Correlations between HFRS (Frequency and Problem-Rating), HFRDIS, HFI, PHQ9 
and GAD7 (n=169), WSAS and use of medical services visits to GP or hospital doctor in 
general (n=40) 
 
 HFRS 
Problem 
Rating 
HFRDIS 
 
HFI WSAS 
 
GAD7 PHQ9 Doctor 
visits past 
6 months 
HFRS 
Frequency 
0.39 ** 0.34 ** 0.22** 0.04  
Ns 
0.08 
ns 
0.12 
ns 
-0.19 
ns 
HFRS 
Problem 
Rating 
 0.74 ** 0.61** 0.42** 0.32** 0.40** 0.40 ** 
HFRDIS 
 
  0.85** 0.69 ** 0.55** 0.55** 0.35 * 
HFI  
 
   0.65** 
 
0.48** 0.53** 0.35* 
 
*Sign at the 0.05 level (2-tailed) 
** Sign at the 0.01 level (2-tailed) 
 
 
 
 
